Mechanistic studies have verified that AK136714 directly targets HuR (ELAVL1) to promote the mRNA stability of TNF-α and IL-1β and increases the transcription of Bim, indicating that AK136714 could function in atherosclerosis and provide potential novel drug targets for atherosclerosis intervention. Here, ELAVL1 is linked to atherosclerosis.